Literature DB >> 18347987

Tumor-associated protein SPIK/TATI suppresses serine protease dependent cell apoptosis.

Xuanyong Lu1, Jason Lamontagne, Felix Lu, Timothy M Block.   

Abstract

Serine protease dependent cell apoptosis (SPDCA) is a recently described caspase independent innate apoptotic pathway. It differs from the traditional caspase dependent apoptotic pathway in that serine proteases, not caspases, are critical to the apoptotic process. The mechanism of SPDCA is still unclear and further investigation is needed to determine any role it may play in maintaining cellular homeostasis and development of disease. The current knowledge about this pathway is limited only to the inhibitory effects of some serine protease inhibitors. Synthetic agents such as pefabloc, AEBSF and TPCK can inhibit this apoptotic process in cultured cells. There is little known, however, about biologically active agents available in the cell which can inhibit SPDCA. Here, we show that over-expression of a cellular protein called serine protease inhibitor Kazal (SPIK/TATI/PSTI) results in a significant decrease in cell susceptibility to SPDCA, suggesting that SPIK is an apoptosis inhibitor suppressing this pathway of apoptosis. Previous work has associated SPIK and cancer development, indicating that this finding will help to open the doorway for further study on the mechanism of SPDCA and the role it may play in cancer development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347987     DOI: 10.1007/s10495-008-0193-x

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  12 in total

1.  Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis.

Authors:  Jason Lamontagne; Mark Pinkerton; Timothy M Block; Xuanyong Lu
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

2.  Impaired spermatogenesis and fertility in mice carrying a mutation in the Spink2 gene expressed predominantly in testes.

Authors:  Boyeon Lee; Inju Park; Sora Jin; Heejin Choi; Jun Tae Kwon; Jihye Kim; Juri Jeong; Byung-Nam Cho; Edward M Eddy; Chunghee Cho
Journal:  J Biol Chem       Date:  2011-06-24       Impact factor: 5.157

3.  Therapeutic targeting of SPINK1-positive prostate cancer.

Authors:  Bushra Ateeq; Scott A Tomlins; Bharathi Laxman; Irfan A Asangani; Qi Cao; Xuhong Cao; Yong Li; Xiaoju Wang; Felix Y Feng; Kenneth J Pienta; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Sci Transl Med       Date:  2011-03-02       Impact factor: 17.956

4.  Role of the inflammatory protein serine protease inhibitor Kazal in preventing cytolytic granule granzyme A-mediated apoptosis.

Authors:  Felix Lu; Jason Lamontagne; Angela Sun; Mark Pinkerton; Timothy Block; Xuanyong Lu
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

5.  SPINK2 is a prognostic biomarker related to immune infiltration in acute myeloid leukemia.

Authors:  Xiaohe Chen; Lifen Zhao; Tian Yu; Jue Zeng; Ming Chen
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

6.  Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer.

Authors:  Wendy Weijia Soon; Lance David Miller; Michael A Black; Cyril Dalmasso; Xiu Bin Chan; Brendan Pang; Chee Wee Ong; Manuel Salto-Tellez; Kartiki V Desai; Edison T Liu
Journal:  EMBO Mol Med       Date:  2011-06-08       Impact factor: 12.137

7.  Regulation of the Pancreatic Exocrine Differentiation Program and Morphogenesis by Onecut 1/Hnf6.

Authors:  Peter A Kropp; Xiaodong Zhu; Maureen Gannon
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-03-01

8.  SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression.

Authors:  R Tiwari; S K Pandey; S Goel; V Bhatia; S Shukla; X Jing; S M Dhanasekaran; B Ateeq
Journal:  Oncogenesis       Date:  2015-08-10       Impact factor: 7.485

9.  The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.

Authors:  Wen-Hao Xu; Shen-Nan Shi; Jun Wang; Yue Xu; Xi Tian; Fang-Ning Wan; Da-Long Cao; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Med Sci Monit       Date:  2019-12-11

10.  Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.

Authors:  Christine Mehner; Erin Miller; Alexandra Hockla; Mathew Coban; S John Weroha; Derek C Radisky; Evette S Radisky
Journal:  Oncogene       Date:  2020-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.